Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

Experimental Neurology

Volumn 184, Issue SUPPL. 1, 2003, Pages 68-79

  Brooks, D J ^a   Frey, K A ^b   Marek, K L ^c   Oakes, D ^d   Paty, D ^e   Prentice, R ^f   Shults, C W ^g   Stoessl, A J ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Inst for Neurodeg Disorders   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; CARBON 11; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE TRANSPORTER; FLUORINE 18; LEVODOPA; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

CONFERENCE PAPER; DIAGNOSTIC IMAGING; DISEASE COURSE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; EVALUATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; SYNAPSE VESICLE;

EID: 0242302336     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.08.008     Document Type: Conference Paper

References (65)

1. Ahlskog J.E., Uitti R.J., O'Connor M.K., Maraganore D.M., Matsumoto J.Y., Stark K.F., Turk M.F., Burnett O.L. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov. Disord. 14:1999;940-946.
2. Albin R.L., Nichols T.E., Frey K.A. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson's disease (Letter). JAMA. 288:2002;311-312.
3. Asenbaum S., Brucke T., Pirker W., Podreka I., Angelberger P., Wenger S., Wober C., Muller C., Deecke L. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J. Nucl. Med. 38:1997;1-6.
4. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington clinical, morphological and neurochemical correlations . J. Neurol. Sci. 20:1973;415-455.
5. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21:2001;6853-6861.
6. Braak H., Braak E. Pathoanatomy of Parkinson's disease. J. Neurol. 247:(Suppl 2):2000;II3-II10.
7. Brown W.D., Taylor M.D., Roberts A.D., Oakes T.R., Schueller M.J., Holden J.E., Malischke L.M., DeJesus O.T., Nickles R.J. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology. 53:1999;1212-1218.
8. 18F-Dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse. 43:2002;201-207.
9. Chan G.L., Holden J.E., Stoessl A.J., Samii A., Doudet D.J., Dobko T., Morrison K.S., Adam M., Schulzer M., Calne D.B., Ruth T.J. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J. Nucl. Med. 40:1999;283-289.
10. De Gruttola V.G., Clax P., DeMets D.L., Downing G.J., Ellenberg S.S., Friedman L., Gail M.H., Prentice R., Wittes J., Zeger S.L. Considerations in the evaluation of surrogate endpoints in clinical trials summary of a National Institutes of Health workshop . Control Clin. Trials. 22:2001;485-502.
11. De Keyser J., Ebinger G., Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann. Neurol. 27:1990;157-161.
12. Dhawan V., Ma Y., Pillai V., Spetsieris P., Chaly T., Belakhlef A., Margouleff C., Eidelberg D. Comparative analysis of striatal FDOPA uptake in Parkinson's disease ratio method versus graphical approach . J. Nucl. Med. 43:2002;1324-1330.
13. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human neostriatum topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor . J. Neurol. Sci. 14:1971;427-455.
14. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., Forno L., Gwinn-Hardy K., Petrucelli L., Hussey J., Singleton A., Tanner C., Hardy J., Langston J.W. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50:2001;293-300.
15. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease substantia nigra regional selectivity . Brain. 114:1991;2283-2301.
16. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:1996;259-272.
17. Frey K.A., Koeppe R.A., Albin R.L., Kilbourn M.R. Losses of VMAT2 in Parkinson's disease and its progression (Abstract). Eur. J. Nucl. Med. 27:2000;927.
18. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., Kuhl D.E. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40:1996;873-884.
19. Guttman M., Stewart D., Hussey D., Wilson A., Houle S., Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 56:2001;1559-1564.
20. Hadjiconstantinou M., Wemlinger T.A., Sylvia C.P., Hubble J.P., Neff N.H. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J. Neurochem. 60:1993;2175-2180.
21. Hattori N., Shimura H., Kubo S., Kitada T., Wang M., Asakawa S., Minashima S., Shimizu N., Suzuki T., Tanaka K., Mizuno Y. Autosomal recessive juvenile parkinsonism a key to understanding nigral degeneration in sporadic Parkinson's disease . Neuropathology. 20:(Suppl):2000;S85-S90.
22. Hauser R.A., Koller W.C., Hubble J.P., Malapira T., Busenbark K., Olanow C.W. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov. Disord. 15:2000;485-489.
23. Horne M.K., Cheng C.H., Wooten G.F. The cerebral metabolism of L-dihydroxyphenylalanine an autoradiographic and biochemical study . Pharmacology. 28:1984;12-26.
24. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
25. 18F]Fluoro-L-dopa metabolism in living human brain a comparison of six analytical methods . J. Cereb. Blood Flow Metab. 13:1993;57-69.
26. 123I]beta-CIT. Mov. Disord. 14:1999;436-442.
27. Jaber M., Jones S., Giros B., Caron M.G. The dopamine transporter a crucial component regulating dopamine transmission . Mov. Disord. 12:1997;629-633.
28. Jennings, D., J. Seibyl J, Oakes D, Eberly S, Marek K. Clinical determinants of progressive dopamine transporter loss measured by β-CIT and SPECT. Mov. Disord. 2002; 17:1104.
29. Kemmerer E.S., Desmond T.J., Albin R.L., Kilbourn M.R., Frey K. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions comparison of L-DOPA and pramipexole . Exp. Neurol. 183:2003;81-86.
30. Kilbourn M.R., Kuszpit K., Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse. 35:2000;250-255.
31. 11C]dihydrotetrabenazine. J. Cereb. Blood Flow Metab. 19:1999;1376-1384.
32. Lang A.E. Clinical rating scales and videotape analysis. Koller W.C., Paulson G. Therapy of Movement Disorders. second ed:1995;21-46 Marcel Decker, New York.
33. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47:2000;493-503.
34. Lehericy S., Brandel J.P., Hirsch E.C., Anglade P., Villares J., Scherman D., Duyckaerts C., Javoy-Agid F., Agid Y. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res. 659:1994;1-9.
35. Liu Y., Edwards R.H. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20:1997;125-156.
36. 123I]Beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 57:2001;2089-2094.
37. McGeer P.L., McGeer E.G., Suzuki J.S. Aging and extrapyramidal function. Arch. Neurol. 34:1977;33-35.
38. Morrish P. Is it time to abandon functional imaging in the study of neuroprotection? Mov. Disord. 17:2002;229-232.
39. 18F]dopa PET. J. Neurol. Neurosurg. Psychiatry. 64:1998;314-319.
40. 18F]CFT PET study . J. Cereb. Blood Flow Metab. 20:2000;1604-1609.
41. Nutt J.G., Carter J.H., Lea E.S., Sexton G.J. Evolution of the response to levodopa during the first 4 years of therapy. Ann. Neurol. 51:2002;686-693.
42. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 287:2002;1653-1661.
43. Pramipexole vs levodopa as initial treatment for Parkinson disease a randomized controlled trial . JAMA. 284:2000;1931-1938.
44. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321:1989;1364-1371.
45. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., Ruth T.J., Calne D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34:1993;331-338.
46. 18F]fluorodopa studies. Myers R., Cunningham V., Bailey D., Jones T. Quantification of Brain Function Using PET. 1996;182-187 San Academic Press, San Diego.
47. 18F-dopa PET study . Brain. 122:1999;1637-1650.
48. Ribeiro M.J., Vidailhet M., Loc'h C., Dupel C., Nguyen J.P., Ponchant M., Dolle F., Peschanski M., Hantraye P., Cesaro P., Samson Y., Remy P. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 59:2002;580-586.
49. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F., Agid Y. Striatal dopamine deficiency in Parkinson's disease role of aging . Ann. Neurol. 26:1989;551-557.
50. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38:1995;589-598.
51. Seibyl J.P., Marek K., Sheff K., Baldwin R.M., Zoghbi S., Zea-Ponce Y., Charney D.S., van Dyck C.H., Hoffer P.B., Innis R.B. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J. Nucl. Med. 38:1997;1453-1459.
52. 10 in early Parkinson's disease evidence of slowing of the functional decline . Arch. Neurol. 59:2002;1541-1550.
53. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34:1993;324-330.
54. Stoessl A.J. Assessing the integrity of the dopamine system in Parkinson's disease how best to do it? Mov. Disord. 16:2001;804-806.
55. Tedroff J., Ekesbo A., Rydin E., Langstrom B., Hagberg G. Regulation of dopaminergic activity in early Parkinson's disease. Ann. Neurol. 46:1999;359-365.
56. 18F]fluoro-DOPA uptake in the human striata. J. Cereb. Blood Flow Metab. 18:1998;951-959.
57. 11C-raclopride PET studies . Neurology. 52:1999;932-937.
58. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294:1995;577-583.
59. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Zoghbi S.S., Baldwin R.M., Innis R.B. Age-related decline in dopamine transporters analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries . Am. J. Geriatr. Psychiatry. 10:2002;36-43.
60. Vingerhoets F.J., Schulzer M., Ruth T.J., Holden J.E., Snow B.J. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease. J. Nucl. Med. 37:1996;421-426.
61. Volkow N.D., Fowler J.S., Wang G.J., Logan J., Schlyer D., MacGregor R., Hitzemann R., Wolf A.P. Decreased dopamine transporters with age in health human subjects. Ann. Neurol. 36:1994;237-239.
62. Whone A.L., Watts R.L., Stoessl J., Davis M., David M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., Brooks D.J. Slower progression of PD with ropinirole versus L-dopa the REAL-PET study . Ann. Neurol. 54:2003;93-101.
63. Wilson J.M., Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16:1996;3507-3510.
64. Wilson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H.B., Hornykiewicz O., Pifl C., Kish S.J. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology. 47:1996;718-726.
65. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons some clinical and basic implications . Trends Neurosci. 13:1990;290-296.